

Table S1 Basic clinicopathological characteristics of patients with or without adjuvant chemotherapy

Variable	ACT (N=109)	Non-ACT (N=19)	P value
Age			
Sex			0.168
Male	75 (88.2%)	10 (11.8%)	
Female	34 (79.1%)	9 (20.9%)	
Distance from anal verge			0.422
≤5cm	58 (82.9%)	12 (17.1%)	
>5cm	51 (87.9%)	7 (12.1%)	
EMVI			0.219
Negative	29 (78.4%)	8 (21.6%)	
Positive	11 (78.6%)	3 (21.4%)	
Unknown	69 (89.6%)	8 (10.4%)	
Procedure			0.169
Open	53 (89.8%)	6 (10.2%)	
Laparoscopic	56 (81.2%)	13 (18.8%)	
ypT stage			0.686
T1	4 (100%)	0 (0%)	
T2	12 (92.3%)	1 (7.7%)	
T3	80 (84.2%)	15 (15.8%)	
T4	13 (81.3%)	3 (18.8%)	
ypN stage			0.082
N0	69 (86.3%)	11 (13.8%)	
N1	30 (90.9%)	3 (9.1%)	
N2	10 (66.7%)	5 (33.3%)	
Perineural invasion			0.204
Negative	63 (88.7%)	8 (11.3%)	
Positive	46 (80.7%)	11 (19.3%)	
Lymphovascular invasion			0.004
Negative	86 (90.5%)	9 (9.5%)	
Positive	23 (69.7%)	10 (30.3%)	
CRM			0.950
Negative	97 (85.1%)	17 (14.9%)	
Positive (<1 mm)	12 (85.7%)	2 (14.3%)	
RAS and BRAF status			0.002
Wild type	22 (73.3%)	8 (26.7%)	
RAS mutation	24 (72.7%)	9 (27.3%)	
BRAF mutation	1 (100%)	0 (0%)	
Unknown	62 (96.9%)	2 (3.1%)	
MMR status			0.271
pMMR	97 (84.3%)	18 (15.7%)	
dMMR	2 (66.7%)	1 (33.3%)	
Unknown	10 (100%)	0 (0%)	

Data are presented as n (%) or mean ± standard deviation. ACT, adjuvant chemotherapy.